ViiV Healthcare

Glaxo's HIV prevention win should lead to upgrades

Viiv’s HIV success shows PrEP is not everything

Gilead’s dominance of the HIV prevention market is set to be challenged by monotherapy.

August 22, 2019

Astra could use a voucher to cement roxadustat’s head start

Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.

October 12, 2018

Proteus and Otsuka sign up for another five years

June 14, 2018

Glaxo doubles down in HIV

November 17, 2017

Upcoming events – US approvals due for Glaxo and Novo Nordisk

February 14, 2017

Gilead and Glaxo’s HIV battle intensifies

December 18, 2015

Viiv-Bristol HIV deal ramps up asset swap stakes

May 07, 2015

Glaxo strategy underwhelms as near-term outlook dims

October 23, 2014

Glaxo’s dire results point to need for a strategy re-think

November 25, 2013

Regulators grant Biogen a big win but AB Science loses out

Load More